Method to Enhance the Effectiveness of HIV Vaccines

Tech ID: 31952 / UC Case 2019-798-0


Researchers at the University of California, Davis have developed adjuvants that promotes the efficacy of HIV vaccines.

Full Description

Vaccines and antiretroviral therapy (ART) have enhanced the life expectancy and quality of life worldwide for many patients carrying the human immunodeficiency virus (HIV). However, some patients respond poorly to current treatment protocols, and ART options are limited in many parts of the world. Thus, additional prevention and treatment alternatives remain a healthcare system priority globally.

Researchers at the University of California, Davis have developed a method of improving a host's immune response to a HIV vaccine by combining the vaccine with an adjuvant. These adjuvants can include interferon-induced proteins and - in some cases - be administered transdermally. In addition, the vaccine itself can be modified to optimize the effective interactions between the vaccine components and the adjuvant. Combining adjuvants with a vaccine creates a stronger patient immune system; as the body's response activates immune cells that help mitigate off-target effects. Increased immunity also enhances the immune response of the host's HIV-relevant organs.


  • Improves HIV vaccine immune response


  • Can trigger specific immune cell response
  • Sustained and stronger immune response (up to 2-fold higher germinal center responses)
  • Immune response also enhanced in HIV-relevant organs

Patent Status

Patent Pending


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Iyer, Smita S.

Other Information

Categorized As